【#时事大家谈 瑞德西韦试验结果出炉，美中结论大相径庭】
中两国几乎同期公布对抗击新冠肺炎药物瑞德西韦的临床试验结果，但结论截然相反。中国医学人员的结论是，瑞德西韦(Remdesivir)对重症患者没有具有统计学意义的临床效果。但美国国立卫生研究院(NIH)紧接着发布的临床研究初步数据称，用药患者比安慰剂患者康复时间快31%。为什么美中两国对同一款药物的临床试验结论会大相径庭？在新冠疫情暴发之初，武汉病毒研究所曾抢注瑞德西韦在中国的使用专利，但现在中国的试验却称该药效果不显著，其背后有哪些因素？《时事大家谈》主持人林枫邀请传染病学博士、前美国沃尔特·里德陆军研究所病毒学研究员林晓旭为您分析解读。 https://youtu.be/Y_aLw35muzw
Pool photo by Ulrich Perrey
Virus Drug Trial Hopeful, Maker Says; Second Trial Finds No Benefit
The F.D.A. said that officials were discussing approval of the drug to treat Covid-19 patients, presumably under emergency use provisions.
HealthApril 29
Remdesivir, a drug designed to stymie viral replication, modestly speeds the recovery of #COVID19 patients, according to a new study.
SCIENCEMAG.ORG
Large trial yields strongest evidence yet that antiviral drug can help COVID-19 patients
MIT Technology Review
A government study of remdesivir showed covid-19 patients got better 30% faster.
This finding is a step towards getting us out of health and economic disasters caused by the pandemic, and hopefully more will follow. Later in the summer new antibody drugs to battle the infections could be available and vaccines could arrive in the months after that.
More than 50,000 courses of Gilead’s experimental Covid-19 therapy are ready to go as soon as the drug is authorized for emergency use, the company's CEO said.
吉利德與中方對瑞德西韋的臨床試驗結果不一 |
吉利德稱，評估其藥物瑞德西韋對新冠患者療效的臨床試驗結果積極
吉利德的新冠藥物瑞德西韋出現好消息，美股受此提振上漲
BRAHMA CHELLANEY
The WHO director-general should be taken to task for his deference to China throughout the COVID-19 crisis.
醜陋的中共盜名與世衛的奴從
看官可能還記得，約十天前，世衛的理事長譚某故意在無意間揭露remdesivir在中國測試"無效"，提早收攤......
看官可能不記得了，此藥在中國被官方提早註冊了.......舉世譁然之後，中共悄悄將試驗中止......
The results of the clinical trials prove ''a drug can block this virus,'' according to US officials.
BBC.COM
Drug has 'clear cut' power to fight coronavirus
美國食品和藥品管理局計劃對抗病毒藥物瑞德西韋進行緊急授權，以作為治療新冠病毒的藥物。美國首席傳染病專家福奇博士對早期結果表示謹慎樂觀。
荷蘭感謝祭｜線上特輯
【真假維梅爾】
DVD 熱銷中 
